Abstract
This study examined the future of Mahoni seed as an aspirant drug for treating diabetes. Mahogany seeds were washed using n-hexane solvent and followed by ethanol solvent. Extracts were measured using a standard spectrophotometric plate reader with acarbose (Glucobayâ). Glucose tolerance was tested in alloxan-challenged mice. The results indicated that the extract had potency against a-glucosidases inhibited through a non-competitive mechanism. The IC50 value of the extract is 4.7 μg/ml, which was lower than 5.7 μg/ml for acarbose and has less activity on glucose tolerance at doses of 120 and 240 mg/kg. As a conclution, purified mahogany seed extract got the ability to be developed as a new antidiabetic drug candidate.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call